EBMT NEWSLETTER | November 2013 | Volume 38 - Issue 3

Important dates

The EBMT Board and CT2 committee has accepted a trial for EBMT sponsorship 

The RACE trial (AAWP): A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients. Co-PIs will be Regis Peffault de Latour (St. Louis, Paris) and Antonio Risitano (Federico II University, Napels)


Ongoing Clinical Trials

The Clinical Trials Offices currently have 2 ongoing trials:
  • RICMAC (Prof Nicolaus Kröger): The RICMAC trial is in the follow up phase. A total of 129 patients have been enrolled. Data collection and processing is in process  for the planned analysis in  January 2014.
  • HCT vs CT Elderly AML (Prof Dietger Niederwieser): This trial has randomised 67 out of 218 patients.  Centres in Australia, Austria and France are now open to recruitment.
If you need information on any of the EBMT’s clinical trials, please contact Alain Barrois: alain.barrois@ebmt.org
Bookmark and Share